PeriOperative ISchemic Evaluation-3 Trial



Status:Recruiting
Conditions:Cardiology, Cardiology
Therapuetic Areas:Cardiology / Vascular Diseases
Healthy:No
Age Range:45 - Any
Updated:11/9/2018
Start Date:July 30, 2018
End Date:December 2022
Contact:Jessica Vincent, MSc
Email:Jessica.Vincent@phri.ca
Phone:905-527-4322

Use our guide to learn which trials are right for you!

This study is a multicentre, international, randomized controlled trial of tranexamic acid
(TXA) versus placebo and, using a partial factorial design, of a perioperative
hypotension-avoidance versus hypertension-avoidance strategy.

The POISE-3 study is a 10,000 patient, multicentre, international, non-inferiority randomized
controlled trial of tranexamic acid (TXA) versus placebo and, using a partial factorial
design, of a perioperative hypotension-avoidance versus hypertension-avoidance strategy. The
primary objective of the study is to determine; if TXA is superior to placebo for the
occurrence of life-threatening, major, and critical organ bleeding, and non-inferior to
placebo for the occurrence of major arterial and venous thrombotic event; and to determine
the impact of a hypotension-avoidance strategy versus a hypertension-avoidance strategy on
the risk of vascular death and major vascular events in patients who are followed for 30 days
after noncardiac surgery.

Inclusion criteria:

1. Undergoing noncardiac surgery;

2. ≥ 45 years of age;

3. Expected to require at least an overnight hospital admission after surgery;

4. Provide written informed consent to participate in the POISE-3 Trial, AND

5. Fulfill ≥1 of the following 6 criteria (A-F):

A. NT-proBNP ≥200 ng/L B. History of coronary artery disease C. History of peripheral
arterial disease D. History of stroke E. Undergoing major vascular surgery; OR F. Any 3 of
9 risk criteria i. Undergoing major surgery; ii. History of congestive heart failure; iii.
History of a transient ischemic attack; iv. Diabetes and currently taking an oral
hypoglycemic agent or insulin; v. Age >70 years; vi. History of hypertension; vii. Serum
creatinine > 175 µmol/L (> 2.0 mg/dl); viii. History of smoking within 2 years of surgery;
ix. Undergoing emergent/urgent surgery.

Exclusion criteria:

1. Planned use of systemic TXA during surgery

2. Hypersensitivity or known allergy to TXA

3. Creatinine clearance <30 mL/min (Modification of Diet in Renal Disease [MDRD])

4. History of seizure disorder

5. Patients with recent stroke, myocardial infarction, acute arterial thrombosis or
venous thromboembolism (<1 month)

6. Patients with subarachnoid hemorrhage within the past 30 days

7. Patients undergoing cranial neurosurgery

8. Previously enrolled in POISE-3 Trial
We found this trial at
10
sites
116th St and Broadway
New York, New York 10027
(212) 854-1754
Columbia University In 1897, the university moved from Forty-ninth Street and Madison Avenue, where it...
?
mi
from
New York, NY
Click here to add this to my saved trials
Chapel Hill, North Carolina 27599
(919) 962-2211
University of North Carolina at Chapel Hill Carolina’s vibrant people and programs attest to the...
?
mi
from
Chapel Hill, NC
Click here to add this to my saved trials
Cleveland, Ohio 44111
?
mi
from
Cleveland, OH
Click here to add this to my saved trials
Cleveland, Ohio 44195
?
mi
from
Cleveland, OH
Click here to add this to my saved trials
410 W 10th Ave
Columbus, Ohio 43210
(614) 293-8652
The Ohio State University, Wexner Medical Center Located in Columbus, The Ohio State University Wexner...
?
mi
from
Columbus, OH
Click here to add this to my saved trials
Houston, Texas 77030
?
mi
from
Houston, TX
Click here to add this to my saved trials
Houston, Texas 77030
?
mi
from
Houston, TX
Click here to add this to my saved trials
Mayfield Heights, Ohio 44124
?
mi
from
Mayfield Heights, OH
Click here to add this to my saved trials
Winston-Salem, North Carolina 27157
?
mi
from
Winston-Salem, NC
Click here to add this to my saved trials
Woolloongabba, Queensland 4102
?
mi
from
Woolloongabba,
Click here to add this to my saved trials